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Abstract
Background: Low utilization of effective coronary heart disease (CHD) prevention strategies may be due
to many factors, but chief among them is the lack of patient involvement in prevention decisions. We
undertook this study to test the effectiveness of an individually-tailored, computerized decision aid about
CHD on patients' discussions with their doctor and their plans for CHD prevention.
Methods: We conducted a pilot randomized trial in a convenience sample of adults with no previous
history of cardiovascular disease to test the effectiveness of an individually-tailored, computerized decision
aid about CHD prevention against a risk factor list that patients could present to their doctor.
Results: We enrolled 75 adults. Mean age was 53. 59% were female, 73% white, and 23% African-
American. 66% had some college education. 43% had a 10-year CHD risk of 0–5%, 25% a risk of 6–10%,
24% a risk of 11–20%, and 5% a risk of > 20%. 78% had at least one option to reduce their CHD risk, but
only 45% accurately identified the strategies best supported by evidence. 41 patients received the decision
aid, 34 received usual care. In unadjusted analysis, the decision aid increased the proportion of patients
who discussed CHD risk reduction with their doctor from 24% to 40% (absolute difference 16%; 95% CI
-4% to +37%) and increased the proportion who had a specific plan to reduce their risk from 24% to 37%
(absolute difference 13%; 95% CI -7% to +34%). In pre-post testing, the decision aid also appeared to
increase the proportion of patients with plans to intervene on their CHD risk (absolute increase ranging
from 21% to 47% for planned medication use and 5% to 16% for planned behavioral interventions).
Conclusion: Our study confirms patients' limited knowledge about their CHD risk and effective risk
reduction options and provides preliminary evidence that an individually-tailored decision aid about CHD
prevention might be expected to increase patients' discussions about CHD prevention with their doctor
and their plans for CHD risk reduction. These findings should be replicated in studies with a larger sample
size and patients at overall higher risk of CHD. 
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Background
Coronary heart disease (CHD) is the leading cause of
death in the United States and significant resources are
being devoted to changing patterns of CHD risk. Yet,
fewer than 50% of patients are using effective CHD pre-
vention strategies for each CHD risk factor. [1-3] Low uti-
lization of these effective CHD prevention strategies may
be due to many factors, but chief among them is the lack
of patient involvement in prevention decisions. Whether
providers acknowledge it or not, patients ultimately
decide whether or not to adhere to CHD prevention strat-
egies. Sub-optimal decision making occurs because
patients lack critical knowledge about CHD risk factors
[4,5], their overall CHD risk [6,7], and effective risk reduc-
tion strategies [8,9], and are offered prevention strategies
that are discordant with their priorities. [10]
Increasing patient involvement in decision making could
increase the effectiveness of decision making and lead to
important reductions in the burden of CHD. Preliminary
evidence suggests that involving patients in the decision
making process improves their knowledge about their
CHD risk factors, their global CHD risk, and their preven-
tion options. [11] Patient involvement may also allow
patients to choose prevention strategies that circumvent
known barriers to CHD risk reduction, thereby increasing
the likelihood of adherence to chosen options. Although
offering patients choices regarding CHD prevention strat-
egies might seem controversial, it has been suggested that
an approach that uses global CHD risk and facilitates
choice helps patients to match the intensity of their CHD
prevention efforts with their concerns for safety, cost, and
the time commitment for treatments. [12]
Decision aids, which are systematically developed tools to
help patients understand and participate in medical deci-
sions, are one means of increasing patient involvement
[13] and might be useful in CHD prevention. Compared
with most decision aids (which help patients make deci-
sions where the evidence of benefit is uncertain or too
close to call across a population of individuals), however,
the goals of a CHD prevention decision aid would be
quite different: to recommend CHD prevention and
encourage a choice among equally acceptable options to
accomplish it. [14] The metric of a successful decision aid
on CHD prevention would, therefore, also be quite differ-
ent. At the decision making level, success would be dem-
onstrated by evidence of patients' intent to intervene on
elevated CHD risk; and, at an outcomes level, success
would be determined by the actual reduction in CHD risk
factors or risk.
In this pilot study, we tested the effects of an individually-
tailored, computerized decision aid about CHD preven-
tion on patients' decision making. Our hypothesis was
that a decision aid, which allowed patients to assess their
CHD risk and weigh their preferences for one or more
treatment options, would increase patients' discussions
with their doctor (in an effort to obtain the medical ther-
apy necessary to reduce CHD risk) and their plans for
CHD risk reduction. Secondarily, we hypothesized that
the decision aid would increase patients' perceptions that
CHD prevention requires an individual decision and their
desire to participate in decision making.
Methods
To involve patients in decision making about CHD pre-
vention, we previously developed a decision aid that pro-
vides patients with basic information about CHD
prevention and encourages patients to make individual-
ized choices about CHD risk reduction. [15,16] In this
study, we tested the effects of that decision aid against a
risk factor list that patients could give to their doctor in a
pilot randomized trial. Our study population, procedures,
and outcomes are described in detail below. An overview
of the design is depicted in Figure 1.
Study population, recruitment, and enrollment
After approval from the University of North Carolina,
School of Medicine Institutional Review Board, we
recruited and enrolled a convenience sample of men and
women, ages 35 to 75, who presented for care at one uni-
versity internal medicine clinic. We included patients if
they had no prior history of cardiovascular disease (CVD)
or other serious medical condition that would limit their
candidacy for screening (i.e. chronic renal failure, cirrho-
sis of the liver, HIV, current non-skin cancer). We
excluded patients if they had participated in intensive risk
factor modification through a diabetes study in our clinic
or if they had no cholesterol checks in the last 3 years, lim-
iting our ability to provide current risk estimates. We also
excluded patients if they were presenting for their first visit
to the clinic or they reported that they were unable to
understand, speak, or read English. We identified poten-
tial participants from daily clinician schedules and, after
obtaining their clinician's permission, approached them
about the study in the clinic waiting room or in their exam
room as they waited for their regularly scheduled visit. We
then obtained informed consent from all patients who
agreed to enroll in the study.
Randomization and blinding
We used a computerized random number generator to
randomize patients to receive either the Heart to Heart
decision aid or a list of their CHD risk factors that they
could present to their doctor. Intervention assignments
were sealed in security envelopes until after subjects
agreed to participate in the study. The research assistant
then broke the seal to determine intervention assignment.
We blinded patients to the purpose of our study by tellingBMC Health Services Research 2006, 6:121 http://www.biomedcentral.com/1472-6963/6/121
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Study design Figure 1
Study design. The dotted line margin denotes interventions and measurement occurring at a single clinical visit.
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them only that they were participating in a study about
"prevention of CHD." Doctors were not blinded and saw
patients in both the decision aid and control group.
The intervention: the Heart to Heart decision aid
After assessing baseline characteristics, we asked all
patients in the intervention group to review the computer-
ized decision aid, Heart to Heart (version 1). [15,16]
Heart to Heart 1) calculates a patient's global risk of CHD
events (e.g. angina, myocardial infarction, and death) in
the next 10 years by combining information about their
age, sex, blood pressure, total and HDL cholesterol, smok-
ing, diabetes, and left ventricular hypertrophy (LVH) sta-
tus using a continuous Framingham equation [17]; 2)
provides patients with individualized information about
their global CHD risk, their personal risk factors, the pros
and cons of pertinent CHD risk-reducing therapies (e.g.
hypertension medication, cholesterol medication, smok-
ing cessation, and aspirin), and the risk reduction achiev-
able after one or more therapeutic interventions; and 3)
encourages patients to choose therapies that are accepta-
ble and feasible for long-term CHD risk reduction. The
tool encourages a good diet and regular exercise for every-
one, but doesn't provide information on how these inter-
ventions modify CHD risk. It also provides a summary
print-out that can be taken to one's visit with his or her
doctor.
To assist patients in using Heart to Heart, a research assist-
ant compiled a list of each patient's most recent risk factor
information (e.g. most recent blood pressure, most recent
total and HDL cholesterol, and electrocardiogram or
echo-reported evidence for LVH in the last 3 years) from
their medical record and provided it to the patient for use
during the decision aid session. Patients then navigated
the decision aid at their own speed from computers in the
patient education room of our internal medicine clinic.
These computers were in a private setting and equipped
with a standard keyboard and mouse to facilitate individ-
ual input and response. A research assistant was available
at all times to answer any questions about decision aid
navigation.
The control group
Patients randomized to the control group received only a
list of their CHD risk factors that they could present to
their doctor. This list included both qualitative identifica-
tion of the risk factors and, where appropriate, a quantita-
tive value for the following risk factors: blood pressure,
total and HDL cholesterol, smoking, diabetes, and left
ventricular hypertrophy (LVH) status.
The provider's role
Providers saw patients for their regularly scheduled medi-
cal visit at the same time as their study related visit, but
had no prescribed role in the study. Our hope was that
providers would facilitate patient decisions to intervene
on their CHD risk, but providers received no special train-
ing about global CHD risk, risk reduction options, or
patient-provider decision making.
Data collection
We collected self-reported data at four points in time dur-
ing a single study visit: during initial eligibility assess-
ment, at baseline, after navigation of the decision aid
(intervention group only), and after the regularly sched-
uled provider visit. We planned this measurement strategy
to capture differences between the decision aid and con-
trol groups in patients' discussions with their provider and
their plans for CHD risk reduction. We secondarily
planned this measurement strategy to look within the
decision aid group to see whether the decision aid
increased patients' perceptions that CHD prevention
requires a decision and their interest in participating in
decision making prior to their visit with their doctor.
Measuring the effects of the decision aid on patient-
provider discussions and patients' plans for CHD risk 
reduction
We measured the main effect of the decision aid on deci-
sion making in 2 ways: 1) by the proportion of patients
who reported they discussed CHD risk with their doctor,
and 2) by the proportion of patients that talked with their
doctor who reported they had a specific plan for CHD risk
reduction at the post-visit survey. We measured patient
discussions with their doctor through a single question:
"Did you and your doctor discuss a plan to lower your
chances of having a heart attack?" Similarly, we measured
plans for CHD risk reduction through a single question:
"At the end of your visit, what did you decide to do, if any-
thing, to lower your chances of heart disease?" We consid-
ered stated intent to adopt any CHD risk reducing
behavior (i.e. aspirin, lipid lowering medication, anti-
hypertension medication, smoking cessation medica-
tions, dietary change, or exercise) in the next 6 months as
sufficient evidence of a plan for CHD risk reduction. We
initially assumed that patients who didn't discuss CHD
prevention with their doctor did not have a specific plan
for risk reduction, but tested this assumption in subse-
quent analyses. Because patients who didn't talk with
their doctor could have made independent plans to inter-
vene on their CHD risk, we secondarily compared the last
stated plans for each individual (regardless of whether
they talked with their doctor) among patients who
received the decision aid and those who did not. For
instance, among those in the decision aid group who did
not talk with their doctor, we considered their stated plan
as the one they reported after viewing the decision aid.
Similarly, among those in the control group who did not
talk with their doctor, we considered their stated plan asBMC Health Services Research 2006, 6:121 http://www.biomedcentral.com/1472-6963/6/121
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that which they reported at baseline. There were too few
patients who talked with their doctor and chose a plan to
make between group comparisons regarding how the
decision aid impacted choice of CHD risk reduction strat-
egy at the end of the study. We did, however, make within
group comparisons as described below.
Measuring within group effects of the decision aid: 
patients' perceptions, their preferred participation in 
decision making, and their risk reduction choices
We measured within group effects of the decision aid
using pre-post comparisons of 1) patients' perceptions
that CHD prevention requires a decision, and 2) patients'
desired participation in decision making. To corroborate
between group differences in plans for CHD risk reduc-
tion, we also measured within group differences in
patients' choices of risk reduction strategy. We assessed
patients' perceptions that CHD prevention requires a deci-
sion using Likert questions assessing agreement with the
following statements: "The same way of lowering the
chance of heart attack is right for everyone" and "I am the
only one who can decide how to best lower my chances of
heart attack." We assessed patients' interest in participat-
ing in decision making using an adaptation of Degner's 5-
item Control Preference Scale. [18] We assessed patients'
plans for CHD risk reduction following the decision aid
by asking "after viewing the decision aid, which of the fol-
lowing things (that you are not currently doing), are you
NOW planning to do to lower your chances of having a
heart attack?" We prompted them to choose one of the six
options mentioned in the decision aid (e.g. hypertension
medication, cholesterol medication, smoking cessation,
aspirin, dietary change, and regular exercise) by providing
these as response options, although we also allowed for
write-ins using an "other" option.
Baseline factors that might affect decision making
Because of our small sample size and the possibility that
randomization may result in unequal groups, we meas-
ured several factors at baseline that might affect patients'
decision making. These included the accuracy of patients'
perceptions about their CHD risk, their knowledge about
effective CHD prevention strategies, and their perceived
barriers to risk reduction. To determine the accuracy of
patients' baseline perceptions about their CHD risk, we
queried them about their absolute CHD risk (e.g. 0–5%,
6–10%, 11–20%, > 20%) and then compared their self-
reported risk with their actual risk, which was calculated
by the Heart to Heart tool and divided into similar catego-
ries. We assessed patients' knowledge about effective CHD
prevention strategies by asking them to choose effective
strategies from a list of 13 possible interventions. The list
included both behavioral (e.g. diet low in saturated fat,
regular exercise, weight loss if overweight, smoking cessa-
tion if smoking) and medication interventions (e.g.
hypertension medication, cholesterol medication, and
aspirin). It also included interventions that do not reduce
the chances of heart disease (e.g. estrogen, vitamin e, cal-
cium, and monitoring morning body temperature) as dis-
tracters. As a conservative measure of overall knowledge,
we calculated the proportion of patients who accurately
identified all four interventions supported by the best evi-
dence (e.g. hypertension medication, cholesterol medica-
tion, aspirin, and smoking cessation). Finally, we used a
series of single questions to query patients about their per-
ception that barriers commonly identified in the literature
would prevent them from initiating CHD prevention (e.g.
lack of knowledge, difficulty determining how important
it is to lower CHD risk, difficulty determine the best way
to lower CHD risk, concerns about other health problems,
lack of symptoms, and difficulty communicating their
needs to their doctor).
Statistical analysis
To assess the success of randomization, we compared the
baseline characteristics of subjects who received the deci-
sion aid with those who were in the control group. We
then used Pearson's chi-square tests (SAS Statistical Soft-
ware, Cary, NC) to evaluate whether the decision aid
increased the proportion of patients who discussed CHD
with their doctor or increased the proportion of patients
with a specific plan for CHD risk reduction. We subse-
quently calculated the within group effects of the decision
aid on 1) patients' perceptions that addressing CHD is
important, 2) their perceptions that CHD prevention
requires a decision, 3) their desires to participate in deci-
sion making, and 4) their stated plans for risk reduction.
We calculated confidence intervals for the differences in
these measures at baseline and post-decision aid using the
exact method for two related binomial proportions (Statx-
act; Cytel Statistical Software, Cambridge, MA).
Sample size estimation
Because this study was a pilot study, sample size was not
based on hypothesis testing, but instead on a reasonable
estimation of the sample size necessary to allow us to look
for trends when comparing data between the decision aid
and control groups.
Results
In accordance with our targeted enrollment and the capa-
bilities of our single research assistant, we approached
212 of the 1247 potentially eligible patients who pre-
sented to our university internal medicine clinic for a
return medical visit during our recruitment period (see
Figure 1). One hundred twenty-nine agreed to participate;
but 42 were determined to be ineligible based on their
prior medical history or other eligibility criteria (17 had
prior cardiovascular disease, 2 had other serious medical
illness that made them a poor candidate for prevention,BMC Health Services Research 2006, 6:121 http://www.biomedcentral.com/1472-6963/6/121
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11 reported they could not read because they were illiter-
ate or did not have their glasses, 11 had no cholesterol
checked in the last three years, and 1 had participated in
the diabetes study in our clinic). There were no significant
differences in the age and gender of those who partici-
pated and those who did not. Eighty-seven patients were
enrolled in the study and randomized to the decision aid
or usual care. Twelve patients (8 in the decision aid group
and 4 in the control group) were subsequently deter-
mined to be ineligible with those in the decision aid
group being slightly more likely to be male and younger.
We, thus, included 75 patients in our final sample (41 in
the decision aid group and 34 in the control group).
The baseline characteristics of included patients are
shown in Tables 1 and 2. Participants in the decision aid
and control groups were similar with regard to their
demographic characteristics, self-perceived health status,
comfort using a computer, accuracy in CHD risk percep-
tion, and their knowledge about effective prevention strat-
egies. Participants in the decision aid group, however, had
more CHD risk factors, a higher CHD risk, more current
Table 1: Baseline participant characteristics
Characteristic Total Group Control Group
(n = 34)
Decision Aid Group
(n = 41)
Mean age (SD) 53 (9) 53 (11) 53 (8)
Female 59% 59% 59%
Race:
White 73% 76% 71%
Black 23% 21% 24%
Education:
At least some college 66% 71% 63%
Good self-perceived health status 67% 68% 66%
CHD Risk Factors
BP > 140/90 39% 47% 31%
TC/HDL ratio > 4 43% 38% 46%
Smoker 39% 29% 46%
Diabetes 8% 6% 10%
Family History of CHD (age < 55) 31% 26% 34%
Actual CHD risk
0–5% 43% 53% 34%
6–10% 25% 21% 27%
10–20% 24% 21% 29%
> 20% 5% 3% 7%
Current CHD Interventions:
Blood pressure med 40% 38% 41%
Cholesterol med 19% 21% 17%
Smoking cessation 13% 6% 19%
Aspirin 39% 32% 44%
Diet low in saturated fat 48% 48% 49%
Exercise regularly 51% 41% 59%
# of Possible Intervention Options for CHD risk*:
0 22% 24% 20%
1 23% 21% 25%
2 34% 42% 28%
31 5 % 9 % 2 0 %
45 % 3 % 8 %
Any Planned intervention, reasonable plans 68% 68% 68%
Any Planned intervention, best evidence interventions only* 56% 63% 51%
Preferred participation in decision making about CHD:
I decide 12% 9% 15%
I decide, consider MD opinion 29% 26% 32%
Share decision 44% 50% 39%
MD decides, considers my opinon 7% 9% 5%
MD decides 7% 6% 7%
Comfort using computer 24% 24% 25%
*This includes hypertension med, cholesterol med, smoking cessation, aspirin.BMC Health Services Research 2006, 6:121 http://www.biomedcentral.com/1472-6963/6/121
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CHD interventions, more potential intervention options,
a greater desire for independent decision making, and
fewer concerns about determining the importance of low-
ering risk and communicating with their doctor than
those in the control group.
The effects of the decision aid on patient-provider 
discussions and patients' plans for CHD risk reduction
In unadjusted analysis (see Table 3), 16% (absolute differ-
ence; 95% CI -4 to +37%) more patients in the decision
aid group talked with their provider about CHD risk
reduction and 13% (absolute difference; 95% CI -7% to
+34%) more had a specific plan to reduce their CHD risk.
When plans were examined more broadly (e.g. including
those who independently made a plan, but didn't talk
with their doctor), results were similar (absolute differ-
ence +16%; 95% CI -1% to 33%). There were too few
patients in our study to support adjusted analyses.
Within group effects of the decision aid: patients' 
perceptions, their preferred participation in decision 
making, and their risk reduction choices
The decision aid did have a modest effect on patients' per-
ception that CHD prevention requires a decision (see
Table 4). Interestingly, there was no concomitant desire
for increased participation in decision making about CHD
Table 2: Baseline factors that might influence decision making
Variable Total Group
(n = 75)
Control Group
(n = 34)
Decision Aid Group
(n = 41)
Perceived CHD Risk
Perceived CHD risk
0–5% 33% 32% 34%
6–10% 32% 29% 34%
11–20% 12% 18% 12%
> 20% 20% 21% 20%
Accurate perception of global CHD risk 22% 23% 21%
Knowledge about Effective Prevention Strategies
Identified "x" as strategy:
HTN med 77% 80% 74%
Cholesterol med 59% 56% 61%
Smoking cessation 99% 100% 98%
Aspirin daily 68% 62% 73%
Diet low in saturated fat 83% 91% 76%
Exercise regularly 97% 97% 98%
Weight loss if overweight 92% 91% 93%
Reduce stress 88% 88% 88%
Drink a glass of red wine daily 39% 38% 39%
Take estrogen (women only) 12% 12% 12%
Take Vitamin E 17% 24% 12%
Take Calcium 11% 18% 5%
Monitor AM body temperature 4% 3% 5%
Accurately identified best strategies to lower CHD risk* 45% 47% 44%
Perceived Barriers to CHD Risk Reduction
Lack of knowledge 82% 85% 81%
Difficulty determining how important it is to lower my risk 65% 76% 56%
Difficulty determining the best way to lower my risk 70% 79% 63%
Concerns about other health problems 57% 65% 51%
Lack of symptoms 58% 59% 56%
Difficulty communicating my needs to my doctor 43% 50% 37%
*This includes knowledge of all four interventions (e.g. hypertension med, cholesterol med, smoking cessation, aspirin) supported by the best 
evidence.BMC Health Services Research 2006, 6:121 http://www.biomedcentral.com/1472-6963/6/121
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with their doctor, but patients in the decision aid group
did plan more interventions after using the decision aid
(see Table 5).
Discussion
Our study confirms prior reports that patients have lim-
ited knowledge about their CHD risk and the effective
options for CHD risk reduction and provides new evi-
dence that an individually-tailored computerized decision
aid about CHD prevention appears to increase the propor-
tion of patients who discuss CHD prevention with their
doctors and the proportion of patients who have a specific
plan for CHD risk reduction. Although results should be
considered preliminary, the magnitude of the effect, if
confirmed would be clinically important. Main findings
were corroborated by within group increases in the per-
ception that CHD prevention requires a personal decision
and by within group increases in specific plans for CHD
risk reduction.
Our finding of an increased proportion of patients with a
specific plan for CHD risk reduction is consistent with
findings from other decision aid studies promoting pre-
vention and a choice among options to accomplish it.
[19-22] This finding is also consistent with studies involv-
ing counseling about individualized CHD risk. For
instance, in a study by Lovibond and colleagues [23], par-
ticipants who received information on their individual
CHD risk, behavioral options for intervention (e.g. dietary
change, regular exercise, weight loss, and stress reduc-
tion), and personalized choice and goal setting, had
greater reductions in CHD risk factors than those who
received standard CHD health education. Given the simi-
lar content of our interventions, Lovibond and colleagues'
Table 3: Between group effects of the decision aid: Presence of patient-provider discussions and specific plans for CHD prevention
Control Group
(n = 34)
Decision Aid Group
(n = 41)
Absolute difference
(95% CI)*
CHD discussion with their doctor 24% 40% 16%
(-4 to +37%)
Have a specific plan to reduce CHD risk and discuss it with their doctor 24% 37% 13%
(-7% to +34%)
Have a specific plan to reduce CHD risk regardless of whether they discuss it 
with their doctor
74% 90% 16%
(-1% to +33%)
*Pearson chi-square tests
Table 4: Within group effects of the decision aid
Baseline
(n = 41)
Post-DA
(n = 41)
Absolute Difference
(95% CI)*
Effect on perception that CHD prevention requires a decision
Same way of lowering the chance of heart attack is right for everyone 40% 33% -7%
(-22% to 7%)
I am the only one who can decide how to best lower my chances of heart attack 30% 43% +13%
(-3% to 29%)
Effect on desire to participate in decision-making
Preferred participation in decision making about CHD:
I decide 15% 10% -5%
(-19% to 7%)
I decide, consider MD opinion 32% 28% -5%
(-19% to 7%)
Share decision 38% 38% 0%
(-15% to 15%)
MD decides, considers my opinion 5% 10% +5%
(-7% to 19%)
MD decides 8% 13% +5%
(-7% to 19%)
* Exact binomial 95% confidence intervalBMC Health Services Research 2006, 6:121 http://www.biomedcentral.com/1472-6963/6/121
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finding offers hope that the plans patients expressed in
our study might be reproducible (and significant in a
larger study) and might additionally translate into actual
CHD risk reduction.
There are a few important considerations in translation of
patients' plans to actual CHD risk reduction, however.
First, successful implementation of some of the options to
lower CHD risk (e.g. hypertension medication, choles-
terol medication) require doctor input. Users of our deci-
sion aid must therefore be able to successfully
communicate their informed decision to their doctor and
gain support for their chosen intervention. This was not
true in the aforementioned study by Lovibond, in which
all risk reduction strategies could be accomplished outside
the clinical encounter. Whether our decision aid encour-
ages users to successfully communicate their decisions to
their doctor and gain the necessary support for interven-
tion is a matter we didn't directly examine. We can not
ignore the seeming paradox, however, that although deci-
sion aid users reported more discussions with their doctor
and more plans for CHD risk reduction, they did not
report a greater desire for shared decision making after
using the decision aid. This issue bears further study to
determine both its repeatability and causes, and whether
we need to add a skill-building session [24,25] to our
intervention to coach patients to interact with their doctor
in order to lower their CHD risk. [26,27] Second, plans for
CHD risk reduction do not ensure action and actual
reduction in CHD risk. We have no guarantee that
patients' chosen plans would actually help them circum-
vent their known barriers to CHD risk reduction. We are
aware that patients are unlikely to adhere to risk reduction
strategies without health system and social supports. [28]
Therefore, we suspect that adjunctive adherence interven-
tions may be needed to bring about actual CHD risk
reduction. [29,30]
Even without modification, individually-tailored CHD
decision aids clearly warrant further testing to address sev-
eral research questions raised by our analysis. First, future
studies should examine how overall CHD risk and the
number of available CHD risk-reducing options affects
patients' choices for risk reduction. Studies providing
patients' global CHD risk estimates to doctors [31,32]
show that doctors are more likely to prescribe risk reduc-
ing agents to patients at higher risk. Whether high risk
patients choose more risk reduction options than low or
moderate risk patients, however, remains to be seen. Sec-
ond, future studies should assess the independent effect of
CHD decision aids on patients and doctors. We didn't
directly measure the effect of our decision aid on doctors'
actions (i.e. via print-outs from the decision aid), but sus-
pect this effect may be as important as increased patient
requests for medication in producing actual risk reduc-
tion. Third, future studies should also determine the
impact of the time spent with the decision aid. Differen-
tial time spent with the decision aid may imply differen-
tial processing of information or exploration of different
information. Although our decision aid is largely con-
structed in linear fashion, patients accessed information
on risk reduction strategies only by following individual
links for each strategy; therefore, those who followed the
links, rather than rushing forward with a priori knowledge
to make decisions, may have made different choices.
Finally, future studies should determine the impact of the
decision aid in the absence of an active comparator. To the
extent that physicians and patients in current clinical prac-
tice think about individual risk factors rather than combi-
nations of multiple risk factors or global risk estimates,
our use of a risk factor list as a comparator may underesti-
mate the expected effects of the decision aid in actual clin-
ical practice.
Future studies should also improve on the methodologi-
cal challenges we encountered in our study. First, future
studies should use a larger sample size: this would provide
greater power to detect the effect of the decision aid,
would improve the random distribution of baseline char-
acteristics, and would also allow for adjustment of rele-
vant confounders. In the current study, we were unable to
adjust for important differences between the intervention
and control groups (e.g. CHD risk, number of options for
risk reduction, desire for independent decision making,
Table 5: Within group effects: Planned risk reduction strategies across with the decision aid
Planned CHD Interventions In Decision Aid Group (n = 41)
Baseline Post-DA Absolute Difference (95% CI) *
BP med, if HTN (n = 13) 8% 54% +46% (9% to 75%)
Cholesterol med, If abnormal chol (n = 19) 5% 26% +21% (-5% to 47%)
Smoking cessation, if smoking (n = 19) 21% 37% +16% (-15% to 44%)
Aspirin, If high risk (> 10%; n = 17) 6% 53% +47% (19% to 72%)
Diet low in saturated fat, all (n = 41) 27% 37% +10% (-8% to 27%)
Exercise regularly, all (n = 41) 29% 34% +5% (-12% to 21%)
*Exact binomial 95% CIBMC Health Services Research 2006, 6:121 http://www.biomedcentral.com/1472-6963/6/121
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Recruitment and enrollment Figure 2
Recruitment and enrollment.
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and reported ease in communicating with their doctor),
which may have biased the results toward a greater effect
of the decision aid than was actually present. Second,
future studies should consider random sampling and
more dedicated study time to avoid attrition after rand-
omization: these would help minimize selection bias.
Although selection bias didn't appear to be a major prob-
lem in our study, we approached a convenience sample of
patients and cannot exclude differences among our study
sample and all of those eligible for inclusion. We also
can't adequately estimate the effects of the small differ-
ences in the number of patients who left the intervention
and control groups after randomization. Finally, future
studies should consider both remote and practice-level
randomization: this would reduce the possible contami-
nation of results that could occur with local randomiza-
tion techniques and doctors in the study who see both the
decision aid and the control patients. The latter may have
biased our results toward a lesser effect of the decision aid
than was actually present.
Conclusion
Our study takes an important first step toward defining
the effect of an individually-tailored computerized deci-
sion aid on patients' plans to talk with their doctor about
CHD prevention and intervene on their CHD risk. Future
work should repeat these findings in a larger sample,
addressing methodological and research issues raised in
the current analysis. If decision aids can be shown to be
repeatedly successful in increasing patients' plans for
CHD risk reductions, the medical community will have an
important new tool to aid the reduction of morbidity and
mortality associated with CHD.
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